41 results about "INSULIN USE" patented technology

The invention relates to a method of food and insulin dose management for a diabetic subject, comprising:providing an intended insulin unit value or an intended carbohydrate unit value representing the amount of insulin or carbohydrate intended for intake by the subject; anddetermining the balance value of either insulin units or carbohydrate units needed to balance with the provided unit value and maintain blood sugar in the subject in a target blood sugar range.

Described and illustrated is a system for management of diabetes that includes an infusion pump, glucose sensor and controller with a method programmed in the controller. The infusion pump is configured to deliver insulin. The glucose sensor senses glucose levels in the subject and provide output signals representative of the glucose levels in the subject. The controller is programmed receives signals from at least one of the glucose sensor and the pump and configured to issue signals to the pump to deliver an amount of insulin determined by a feedback controller that utilizes a model predictive control based on desired glucose levels, insulin amount delivered and measured glucose levels of the subject. The controller is also configured to deliver insulin using a tuning factor (R) for a model predictive controller in the microcontroller as a conservative setting otherwise the system maintains a current tuning factor (R) for the controller.

Described and illustrated is a system for management of diabetes that includes an infusion pump, glucose sensor and controller with a method programmed into the controller. The infusion pump is configured to deliver insulin to a subject. The glucose sensor is configured to sense glucose levels in the subject and provide output signals representative of the glucose levels in the subject. The controller is programmed receives signals from at least one of the glucose sensor and the pump and configured to issue signals to the pump to deliver an amount of insulin determined by a feedback controller that utilizes a model predictive control of the subject based on desired glucose levels, insulin amount delivered and measured glucose levels of the subject. The controller is also configured to deliver insulin using a tuning factor based on either one of an omission index module or a calibration index module.

A pharmaceutical formulation for absorption through oral mucosae comprising an effective amount of (a) a pharmaceutical agent in mixed micellar form, (b) at least one micelle-forming compound selected from the group comprising an alkali metal alkyl sulfate and a polyoxyethylene sorbitan monooleate, (c) a block copolymer of polyoxyethylene and polyoxypropylene, (d) at least one additional micelle-forming compound, and (e) a suitable solvent. The invention also provides a metered dose dispenser (aerosol or non-aerosol) containing the present formulation and a method of administering insulin using the metered dose dispenser comprising administering split doses of a formulation containing insulin before and after each meal.

A health-monitoring device assesses the health of a user based on levels of two analytes in a biological fluid. A first analyte that is utilized to assess a user's health is a fat metabolism analyte, such as ketones, free fatty acids and glycerol, which is indicative of fat metabolism. A second analyte that is utilized is a glucose metabolism analyte, such as glucose. The levels of the two analytes may be used to assess insulin sensitivity, to detect both recent hypoglycemia and the cause of high glucose levels, and / or to guide therapeutic intervention. The dual analyte model may calculate a discrepancy between an actual insulin activity level and a theoretical insulin activity level. The dual analyte model of the present invention may be used to identify individuals at risk for metabolic syndrome, insulin resistance and non-insulin dependent diabetes, and allows monitoring of the progression of those disease states, as well as progress made by therapeutic interventions.

Described and illustrated is a system for management of diabetes that includes an infusion pump, glucose sensor and controller with a method programmed in the controller. The infusion pump is configured to deliver insulin. The glucose sensor senses glucose levels in the subject and provide output signals representative of the glucose levels in the subject. The controller is programmed receives signals from at least one of the glucose sensor and the pump and configured to issue signals to the pump to deliver an amount of insulin determined by a feedback controller that utilizes a model predictive control based on desired glucose levels, insulin amount delivered and measured glucose levels of the subject. The controller is also configured to deliver insulin using a tuning factor (R) for a model predictive controller in the microcontroller as a conservative setting otherwise the system maintains a current tuning factor (R) for the controller.

The present invention relates to an adipocyte Insulin adplnsl with Insulin A and B chains of SEQ ID Nos. 1 and 2, a effective method of treating type 2 diabetes in a subject using adipocyte insulin, said method comprising steps of administering the insulin to a diabetic intraperitoneally, an Insulin gene of SEQ ID No. 3, a process of isolating protein Insulin from the adipocytes of the Carp, said method comprising steps of reverse transcripting RNA of adipocytes to obtain cDNA, using oligonucleotide primers of SEQ ID Nos. 5 and 5 to identify AdpInsl gene from cDNA, and deducing amino acid sequence from cDNA to obtain protein Insulin, and an adipocyte of Catla Catla useful for producing the said Insulin.

The present invention is made to provide a safe and efficient blood glucose measuring device capable of collectively performing blood glucose measurement process and collectively performing insulin administration process on many patients, while ruling out the risk of misidentification and misprescription among the patients. When having read a patient ID with a patient ID reading section, a control section identifies a record of the patient of a measurement / administration results table. The control section does not perform blood glucose measurement on the patient of the identified record which shows that a blood glucose measurement flag is “true” and an insulin administration confirmation flag is “false”, and displays an insulin dosage on a display unit with respect to the patient by referring to a prescription information table based on the blood glucose level has been measured. The control section does not display the insulin dosage on the display unit again for the patient whose record is identified which shows that the insulin administration confirmation flag is “true”.

This invention pertains to a method that can control, treat, and prevent Diabetes Mellitus. The method includes means of administering a potent product, including mainly the active ingredient Linalool, in any one of several forms, alone or with other additives and catalysts, such as vitamin E to enable the body to handle and control, then correct the complications of Diabetes Mellitus. A modest percentage of users suffering from this disease can be cured completely while the majority of others improve remarkably and experience lower blood glucose and reduce the glycated hemoglobin HbAlc readings to what are medically acceptable and healthy levels. Others, who are vulnerable to the disease due to hereditary factors, or other reasons, can help prevent it. The method works in several ways, including activation of the pancreas and re-establishing the ability of body cells to utilize and handle better and well, the glucose in the blood, and regulate the level of natural insulin in the body. The method employs Linalool in any one of its forms that can be found naturally or synthetically.

The name of the invention is glucose-reducing tea for treating diabetes, which belongs to the technical field of pure traditional Chinese medicine and is mainly used for solving the problems that the all the existing drugs adopt the way of pure stimulation on insulin secretion or exogenous increase of insulin for controlling blood glucose, and can not realize self-regulation of the blood glucose fundamentally, and the long-term administration can lead the blood glucose to fluctuate. The glucose-reducing tea uses the tea formulation for serving patients with diabetes for the first time, thus the administration is convenient, and the effects are significant. The glucose-reducing tea is mainly characterized by being a medicament prepared from the following raw materials in parts by weight: 10-25 parts of crude common yam rhizome, 10-25 parts of membranous milkvetch root, 5-15 parts of common anemarrhena rhizome, 10-25 parts of dried rehmannia root, 10-25 parts of kudzuvine root, 10-25 parts of mongolian snakegourd root, 5-15 parts of barbary wolfberry fruit and 5-15 parts of Chinese magnoliavine fruit. The glucose-reducing tea has the characteristics of rapidly reducing glucose, keeping the blood glucose stable in the normal range, nourishing liver, tonifying kidney, nourishing and regulating stomach, further improving resistance of a human body, reducing glucose, tonifying kidney, regulating blood glucose, regulating a metabolic system and leading the diabetes of the patients to disappear thoroughly, is mainly used for treating the patients with mild and moderate diabetes, and can rapidly relieve or eliminate symptoms and reduce complications.

The invention discloses fast nutritional staple food for diabetes. The product comprises the following raw materials: corn, oats, buckwheat, pumpkin powder and the like. The staple food has the following beneficial effects: firstly, the staple food can provide sufficient calories for eaters and has standard staple food characteristics; the product also has good edibility and can well meet the rigorous demands of the eaters; plenty of celluloses in the product are beneficial to promoting the blood sugar to keep stable; rich trace elements such as chromium, magnesium, zinc, calcium and selenium have the blood sugar reducing effect like insulin and assist insulin to play a role in reducing the blood sugar; and rich vitamins B and E can be used for reducing the complications in eyes, kidneys, heart and blood vessels and the like which are liable to the diabetes patients.

The present invention provides an insulin-specific assay and an assay reagent capable of sensitively and specifically assaying insulin using an antibody having a property of reacting with insulin bound to an anti-insulin antibody while not reacting with insulin not bound to an anti-insulin antibody, without being affected by proinsulin and insulin analogs.

The invention discloses a medium composition for inducing mesenchymal stem cells into insulin-secreting cells. The medium composition comprises a medium A, a medium B and a medium C. The medium A comprises the following solutes: a fetal calf serum with a concentration of 4.75 to 5.25 ml / L and activin A with a concentration of 4.75 to 5.25ng / mL. The medium B comprises the following solutes: retinoic acid with a concentration of 0.95 * 10<-5> to 1.05 * 10<-5> mol / L, EGF with a concentration of 19 to 21ng / ml, bFGF with a concentration of 19 to 21ng / ml, glutamine with a concentration of 1.9 to 2.1 mmol / L, 0.95 to 1.05% of non-essential amino acids and 1.9 to 2.1% of B27. The medium C comprises the following solutes: a fetal bovine serum with a concentration of 4.5 to 5.5 ml / L, exendin-4 with a concentration of 19 to 21 ng / ml, activin A with a concentration of 9.5 to 10.5 ng / ml, nicotinamide with a concentration of 9.5 to 10.5 mmol / L, 1.9 to 2.1% of B27 and 0.95 to 1.05% of N2. An induction culture method provided by the invention is applicable to a variety of tissue-derived mesenchymal stem cells and has the advantages of no introduction of viruses, easy operation and high efficiency.

The present invention refers to a method for producing a human insulin analogue with high efficiency and excellent yield, by means of a biotechnological process comprising transformation of a Pichia pastoris yeast strain. In particular, the invention refers to a biotechnological process for obtaining aspart insulin.

The invention belongs to the field of biology and particularly relates to the research field of an endocrine metabolic disease type 2 diabetes mellitus, and more particularly relates to an induction feed for establishment of a type 2 diabetes mellitus animal model or an obese animal model and application and an application method of the induction feed. The invention discloses the induction feed. The diabetes mellitus induction feed comprises 0.01-0.5% of a food preservative. The invention further discloses the application and the application method for establishment of the type 2 diabetes mellitus animal model by using the diabetes mellitus induction feed. Through a selecting optimal experiment on growth indexes of a mouse by food preservatives in different contents and types, the induction feed is relatively good in inhibitory effect of intestinal flora and relatively good in blood glucose raising and weight-gaining effect. After the mouse is fed by the feed for 2-5 months, weight, blood glucose, blood lipid, urea acid, insulin and the like of the mouse are remarkably increased. A food-borne animal model which is similar in duration and pathology with type 2 diabetes mellitus with hyperinsulinemia, hyperuricemia, insulin resistance and insulin secretion deficiency is successfully established. The induction feed has remarkable innovative significance and practical value.

The present invention relates to human insulin expression plasmids and a method for producing insulin using the same. The plasmids comprise a sequence encoding a compound of the formula R—B—X-A, in which R is a leader peptide of the formula of Met-Thr-Met-Ile-Thr-Y (SEQ ID NO: 36), in which Y is one selected from lysine, arginine, a peptide containing lysine as an amino acid at its C-terminal, or a peptide containing arginine as an amino acid at its C-terminal; B is human insulin B-chain or analogue thereof; X is a peptide connecting B with A; and A is human insulin A-chain or analogue thereof. The method for preparing insulin using the plasmids according to the present invention converts the proinsulin fusion protein into human insulin in a single enzymatic cleavage process and minimizes the generation of by-products after the enzymatic cleavage, thereby producing insulin at a high yield. Therefore, the plasmids according to the present invention and the method for preparing insulin using the same can be usefully applied to the industrial mass-production of human insulin.

A computer-implemented method for recommending an optimum insulin bolus dosage to a patient is described. The computer-implemented method includes receiving diabetes related data from the patient. The computer implemented method further includes determining a plurality of insulin bolus dosages using a plurality of insulin bolus calculators. The plurality of insulin bolus dosages are calculated based on the diabetes related data. Thereafter, an optimum insulin bolus dosage is determined based on the plurality of insulin bolus dosages. The optimum insulin bolus dosage is then presented to the patient.

The present invention relates to a health care product, in particular to a post meal glucose-stabilized convenient nutrition conjee and the preparation method thereof, which can stabilize the blood glucose after meal. The present invention provides a convenient nutrition conjee which can stabilized the blood glucose after meal, wherein the brown rice and buckwheat rice in the prescription keep the nutritious elements and the fibers to the largest extent, while the rutin and chlorophyll contained in the buckwheat rice is what the other corn corps lack, and the minerals and the vitamins of the buckwheat rice are also higher than the level of the other crops, wherein based on the medical research, the flavone of the buckwheat rice has multiple functions of anti-oxidation, decrease blood glucose, and decrease blood lipid. The post meal glucose-stabilized convenient nutrition conjee provided by the present invention can balance the nutrition, act against oxidization, meliorate the insulin resistance, decrease the dosage of the glucose-lowering drugs, improve the insulin utilization rate of the patient, effectively improve the level of oral glucose tolerance test (OGTT) and the level of glycated haemoglobin (HbALC), improve the quality of life of the patient, prevent from the complications, and be in favor of the intake by the diabetes patient.

The invention discloses a natural plant composition capable of repairing an insulin secretion function of pancreas beta-cells and applicable to type II patients with diabetes mellitus. The natural plant composition is prepared from the following components in parts by weight: 5-10 parts of horseradish tree leaves, 3-5 parts of mulberry leaf extract, 2-5 parts of kudzu vine root extract and 3-8 parts of rhizoma polygonati extract. The horseradish tree leaves contain abundant proteins, mineral elements and vitamins, also contain 17 types of amino acids and contain11 types of amino acids necessary for human bodies, particularly lysine and threonine. By adopting a synergistic effect between total flavones of the horseradish tree leaves and the other components, the natural plant composition has a better effect of lowering blood glucose. Compared with current chemical medicines for treating the diabetes mellitus, the pure natural plant composition is adopted so that untoward effects and side effects are remarkably reduced, and a medicine treatment effect is better; the medication compliance of the patients with the diabetes mellitus is remarkably improved. Flavone substances of the kudzu vine root extract is combined with mulberry leaf extract deoxynojirimycin to form a novel substance, namely cics, and the novel substance has the effects of lowering the blood glucose, lowering blood lipid and resisting inflammation and the like.

Materials derived from cinnamon can be administered orally to humans or animals for the purpose of controlling blood glucose as well improving glucose tolerance. Controlling glucose metabolism is essential for those with impaired glucose metabolism as is the case for those with Type II diabetes where insulin function is not properly functioning. Such administration can also be used for the purpose of enhancing nutrient transport for purposes of athletic performance and controlling bodyweight and body fat levels. Similarly related, such administration can also be used for the purpose of enhancing creatine transport into excitable tissues such as skeletal muscle. The material can be administered as extracts of cinnamon and can be administered in a variety of ways including capsules, tablets, powdered beverages, bars, gels or drinks.

The invention discloses a blood-sugar-reducing composition and application thereof. In the blood-sugar-reducing composition, insulin and selenium are combined according to an insulin-selenium ratio of 1U:(1-40mu g).In the blood-sugar-reducing composition, the insulin and selenium are subjected to compound combination, and the antioxidation action and the insulin-like action of the selenium further provide a foundation for the reasonable compound combination of the insulin and selenium. The compound composition can reduce the blood sugar level of a diabetic, and the blood sugar concentration can be reduced to about 80% two hours after the composition is taken, wherein the insulin has more obvious blood-sugar-reducing action, thereby being the main drug; and sodium selenite has less action in comparison with the insulin, thereby being the adjuvant drug. The combination of the selenium and the insulin can reduce the dose of the insulin, and the combination has a better curative effect in comparison with the single use of the insulin.

The invention discloses novel diabetes blood-glucose-reducing therapeutic equipment which comprises an incubator body. A vacuum inner container is fixed in the incubator body. A semiconductor thermoelectric cooler is fixed in a through groove in the middle of the bottom face in the vacuum inner container. A second draught fan is fixed to the right side of the bottom face in the vacuum inner container. An air outlet of the second draught fan faces the semiconductor thermoelectric cooler. A temperature sensor and a heating device are fixed to the rear side face in the vacuum inner container. The inner wall of the vacuum inner container and a partition plate are clamped. When a diabetes patient needs to inject insulin, a buzzer sends out buzz to remind the diabetes patient to inject insulin so that blood glucose can be kept stable. The novel diabetes blood-glucose-reducing therapeutic equipment is small in size, simple in structure and convenient to carry, automatically adjusts the temperature in the vacuum inner container, is convenient for a user to use and stores insulin in a proper temperature environment; due to the second draught fan, the air circulation in the vacuum inner container is enhanced, and the air temperature in the vacuum inner container is uniform.

The present invention relates to an insulin analog that has reduced insulin receptor binding affinity for the purpose of increasing the blood half-life of insulin, and long-acting insulin, a conjugate, and a method of preparing long-acting insulin using the same.

The invention discloses an application of a traditional Chinese medicine composition in the preparation of medicines for preparing diabetic ketoacidosis complicated with leukemoid reaction. The traditional Chinese medicine composition comprises herbal medicines such as ginseng, rhizoma polygonati, rhizoma atractylodis, radix sophorae flavescentis, poria cocos, dwarf lilyturf tuber, prepared fleeceflower root, rehmannia root, dogwood, coptidis rhizoma and fortune eupatorium herb. The traditional Chinese medicine composition is mainly used for tonifying qi and yin, strengthening spleen and transferring body fluid, and has the effects of clearing away heat, eliminating dampness and promoting blood circulation to remove meridian obstruction. After the traditional Chinese medicine composition is taken, the dosage of insulin used by patients is gradually reduced, the blood glucose control is normal and stable, the time of urine acetone bodies turning to negative is obviously shortened, and the state of illness can be controlled as soon as possible.

The invention discloses a method for adjusting blood sugar through insulin. The tabulation method is adopted to adjust blood sugar through insulin in the morning (noon) or evening, and core contents of the method are simply introduced through the following points: firstly, the method is suitable for common diabetics to perform self blood sugar management and assisting doctors to perform blood sugar control on diabetics; secondly, premixed insulin widely used in China comprises NovoRapid 30, Novolin 30R and Humulin 30 / 70; thirdly, the quantity of insulin demanded by a patient every day is computed through a traditional formula firstly, then the quantity of insulin demanded is respectively listed in the morning and evening, different blood sugar ranges are respectively listed, different insulin doses are injected correspondingly for a meal, the higher the blood sugar is before the meal, the higher the insulin dose is required to be injected for the meal, and then different insulin doses in different blood sugar ranges are simultaneously increased or reduced according to the blood sugar before the next meal, so that the blood sugar is adjusted and controlled. The method reduces the occurrence rate of hypoglycemia, and has a good control effect.

The invention discloses a use of a 2,4-thiazolidinedione compound K145 in the preparation of a diabetes treatment drug. Diabetic ob / ob and db / db mice are intervened with the K145 by intraperitoneal injection and intragastric administration, a result of detection shows that the fasting blood-glucose values of two groups of the diabetic mice are significantly reduced, the insulin resistance of peripheral tissues is enhanced, the glucose output capability of liver tissues is enhanced, the expression of hepatic gluconeogenesis-related genes PEPCK and G6Pase is reduced, and after the K145 is addedto hepatocytes, the phosphorylation level of a hepatocyte insulin signaling molecule Akt rises, and the expression of the hepatic gluconeogenesis-related genes is reduced. A result of blood glucose lowering experiments of experimental animals shows that the compound has a good blood sugar lowering effect on the diabetic mice.